Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial

Stock Information for Veru Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Veru Inc.

Veru to Report Fiscal Year 2025 Financial Results on December 17th
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
Veru to Present Two Abstracts at ObesityWeek 2025
Veru Announces Proposed Public Offering
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
Veru Announces Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.